Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP24A1 | Q07973 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.38 |
| ▸ | VDR | P11473 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | PSMD10 | O75832 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 2/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2340055 | 0.92 | MEN1 (0.48) | MEN1KMT2ACYP24A1CA12CA1 | |
| SCHEMBL8339482 | 0.89 | CYP24A1 (0.40) | MEN1KMT2ACYP24A1CA12CA1 | |
| SCHEMBL6098372 | 0.87 | ALDH1A1 (0.48) | MEN1KMT2ACYP24A1CA12CA1 | |
| SCHEMBL2340512 | 0.87 | ALDH1A1 (0.49) | MEN1KMT2ACYP24A1VDRALDH1A1 | |
| SCHEMBL2337256 | 0.86 | REN (0.44) | MEN1KMT2APKM | |
| SCHEMBL5870619 | 0.84 | MEN1 (0.54) | MEN1KMT2AADAM17VDRALDH1A1 | |
| SCHEMBL2246161 | 0.83 | ALDH1A1 (0.49) | CYP24A1CA12CA1CA9ALDH1A1 | |
| SCHEMBL12737574 | 0.82 | ALDH1A1 (0.50) | CYP24A1CA12CA1CA9VDR | |
| SCHEMBL21618180 | 0.82 | ALDH1A1 (0.50) | CYP24A1CA12CA1CA9VDR | |
| SCHEMBL25311278 | 0.82 | ALDH1A1 (0.48) | CYP24A1CA12CA1CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842688-B2 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2010-11-30 | — | — | US | disclosed |
| US-7790715-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-07 | — | — | US | disclosed |
| US-20090012055-A1 | Organic compounds | HEROLD PETER | 2009-01-08 | — | — | US | disclosed |
| EP-1961752-A2 | Piperidine Compounds | Speedel Experimenta AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
| EP-1670760-A1 | ORGANIC COMPOUNDS | Speedel Experimenta AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005061457-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012055-A1 | Organic compounds | REN, ACE, ACE2 | MEN1 2817/4885KMT2A 3839/4885CYP24A1 831/4885 |
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | MEN1 2817/4885KMT2A 3839/4885CYP24A1 831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.